Page 3 - Stroke Conference News Today

New study utilizes Hyperfine, Inc. portable MRI system in monitoring brain injury and evaluating physiological impacts...

ISC23: Late-breaking results from STROKE AF study reinforce importance of long-term continuous cardiac monitoring in ischemic stroke patients DUBLIN and DALLAS, Feb. 8, 2023 /CNW/ -- Medtronic today... | February 8, 2023

REDWOOD CITY, CA / ACCESSWIRE / February 3, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, is excited to announce

The ENCHANTED2/MT trial, which was investigating intensive lowering of blood pressure in acute ischemic stroke patients after mechanical thrombectomy, has been stopped early due to safety concerns.

Although dual antiplatelet therapy using cilostazol is associated with a lower risk of recurrent stroke in men, it has no significant benefit for women, a sub-analysis of CSPS.com results suggests.

Conference Call and Webcast March 15 at 8:00 am Eastern Time / 7:00 am Central Time Currently Dosing Patients in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial Team Expanded with Addition... | March 14, 2022

Pediatric patients with large-vessel occlusion stroke are six times more likely to have significant disability if they do not undergo mechanical thrombectomy, a retrospective study suggests.

Registry data suggest that among clots rich in red blood cells, those with low platelet content are associated with less disability and lower mortality after mechanical thrombectomy.

A prospective, observational study suggests that mobile stroke units are associated with lower stroke-related costs per quality-adjusted life year compared with standard care.

A new observational study uncovers significant cognitive decline in the years after a myocardial infarction, although not immediately after the event.